Featured News

02/16/2010
CENTOCOR ORTHO BIOTECH PRODUCTS AND AMGEN FINALIZE ESA RISK EVALUATION AND MITIGATION STRATEGY (REMS) WITH FDA

01/14/2010
STELARATM SHOWS GREATER EFFICACY THAN ETANERCEPT FOR TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS: PHASE 3 COMPARATOR STUDY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

12/17/2009
Centocor Ortho Biotech Products, L.P. Statement on Prescribing Information Update for PROCRIT® (Epoetin alfa)

10/21/2009
NEW SIMPONI™ DATA SHOW INHIBITION OF JOINT DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS

10/21/2009
NEW SIMPONI™ DATA SHOW LONG-TERM EFFICACY IN TREATMENT OF RHEUMATOID ARTHRITIS

09/25/2009
STELARA™ (USTEKINUMAB) RECEIVES FDA APPROVAL FOR TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS WITH FOUR-TIMES-A-YEAR MAINTENANCE DOSING

09/11/2009
CENTOCOR ORTHO BIOTECH RECEIVES FDA COMPLETE RESPONSE LETTER REGARDING DOXIL® FOR THE TREATMENT OF ADVANCED BREAST CANCER

09/10/2009
FDA ISSUES COMPLETE RESPONSE LETTER FOR TRABECTEDIN COMBINED WITH DOXIL

09/09/2009
PRO QUARTERBACK DAVID GARRARD AIMS TO SCORE BIG FOR CROHN'S DISEASE DURING THE 2009 FOOTBALL SEASON

07/29/2009
NEW WAY RATM TALK SHOW PREMIERES ONLINE FOR PEOPLE LIVING WITH RHEUMATOID ARTHRITIS (RA)

07/27/2009
CENTOCOR ORTHO BIOTECH STATEMENT ON FDA ODAC OPINION REGARDING DOXIL® FOR TREATMENT OF ADVANCED BREAST CANCER

07/27/2009
CENTOCOR ORTHO BIOTECH STATEMENT ON THE FDA ODAC OPINION REGARDING TRABECTEDIN FOR RELAPSED OVARIAN CANCER

07/10/2009
JOHNSON & JOHNSON COMPLETES ACQUISITION OF COUGAR BIOTECHNOLOGY

07/10/2009
NEW ONE-YEAR DATA FROM REMICADE® SONIC TRIAL SHOW SUSTAINED EFFICACY COMPARED WITH AZATHIOPRINE IN TREATMENT OF CROHN'S DISEASE

07/02/2009
CENTOCOR ORTHO BIOTECH INC. AWARDED $1.67 BILLION PATENT JURY VERDICT FROM ABBOTT LABORATORIES

07/02/2009
NEW ANALYSIS SHOWS EFFICACY OF SIMPONITM (GOLIMUMAB) IN ANTI-TNF EXPERIENCED RHEUMATOID ARTHRITIS PATIENTS

07/02/2009
SIMPONITM(GOLIMUMAB) RECEIVES POSITIVE OPINION FROM CHMP FOR ONCE-MONTHLY SUBCUTANEOUS TREATMENT OF RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS

07/02/2009
TWO-YEAR DATA SHOW PATIENTS RECEIVING SIMPONITM (GOLIMUMAB) EXPERIENCED SUSTAINED IMPROVEMENT IN SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS

05/29/2009
CENTOCOR ORTHO BIOTECH DATA TO BE PRESENTED AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

05/26/2009
FDA EXTENDS REVIEW TIMELINE FOR STELARA™ (USTEKINUMAB) BIOLOGIC LICENSE APPLICATION BY THREE MONTHS

05/13/2009
Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa

05/01/2009
WINNER OF 2009 CURE MAGAZINE EXTRAORDINARY HEALER AWARD ANNOUNCED

04/24/2009
SIMPONITM (GOLIMUMAB) RECEIVES FDA APPROVAL AS FIRST ONCE-MONTHLY ANTI-TNF FOR TREATMENT OF RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS

04/13/2009
HEALTH CANADA APPROVES SIMPONITM(GOLIMUMAB) FOR TREATMENT OF RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS